Core Points - The article discusses the increasing trend of graduate students in China choosing to withdraw from their programs, highlighting the pressures and challenges they face in academia [1][3][4] - It presents statistics indicating a significant number of students are unable to graduate on time, with one in four graduate students not completing their programs [2][3] - The narrative includes personal stories of students who have withdrawn, illustrating their struggles with academic pressure, mental health, and the expectations placed upon them by family and society [5][6][12] Group 1 - The number of applicants for the national master's degree examination in 2025 is projected to be 3.88 million, with only 872,200 spots available, leading to nearly 3 million students being unsuccessful [2] - Approximately 500,000 students drop out of Chinese universities each year, with a dropout rate of nearly 3% among enrolled students [2] - The pressure faced by graduate students has intensified despite an increase in enrollment opportunities, leading to feelings of burnout and internal conflict [3][4] Group 2 - Students who withdraw often do so after prolonged periods of distress, indicating that the decision is not made lightly but is a culmination of various pressures [5][12] - Personal accounts reveal that students feel trapped in their academic paths, often driven by external expectations rather than personal interests [14][22] - The article emphasizes the emotional toll of academic life, with students experiencing anxiety, insomnia, and a sense of inadequacy [15][49] Group 3 - The transition from undergraduate studies to graduate research is marked by a shift in focus that many students find challenging, leading to feelings of being overwhelmed [18][19] - The article highlights the competitive nature of graduate programs and the lack of support that students often encounter, contributing to their decision to leave [20][27] - The experiences shared by students illustrate a broader issue within the academic system, where the pressure to succeed can lead to mental health struggles and a reevaluation of personal goals [26][49] Group 4 - The withdrawal from graduate programs is framed as a form of liberation for some students, allowing them to pursue paths that align more closely with their personal values and interests [64] - The article discusses the societal stigma surrounding dropping out, contrasting it with the acceptance of pursuing higher education as a norm [63] - Students express a desire to redefine success on their own terms, moving away from traditional academic achievements towards more fulfilling life choices [60][64]

长江商报消息通过收购，上海医药（601607）(601607.SH、02607.HK)盈利能力大幅提升。 7月9日晚间，上海医药公告显示，公司预计2025年上半年实现净利润为44.50亿元，同比将增加15.08亿元，涨幅约 52%。 对此，上海医药解释称，公司完成收购上海和黄药业有限公司(以下简称"和黄药业")10%股权的交割手续，公司合 计持有和黄药业股权比例从50%变更至60%，并将其纳入合并报表范围，公司对其会计核算由合营企业的权益法 核算变更为按子公司核算。根据会计准则规定，上市公司投资收益上涨。 上半年净利预增52% 上海医药是沪港两地上市的大型医药产业集团，是控股股东上实集团旗下大健康产业板块核心企业，主营业务医 药工业、医药商业均居中国领先地位，公司医药工业位列全球制药企业50强。 7月9日晚间，上海医药发布公告称，经财务部门初步测算，公司预计2025年上半年度实现归属于母公司所有者的 净利润为44.50亿元，与上年同期相比，将增加15.08亿元，同比增长约52%。 对于利润增长，上海医药介绍，公司于2025年4月25日完成收购上海和黄药业有限公司(以下简称"和黄药业")10% 股权的交割手续， ...

Core Viewpoint - The restructuring plan of Huada Jiutian (301269.SZ) has failed after three and a half months, leading to a significant drop in its stock price and market value [1][6]. Group 1: Restructuring Details - Huada Jiutian announced the termination of its major asset restructuring on July 9, 2025, which aimed to acquire 100% of Chip and Semiconductor Technology (Shanghai) Co., Ltd. [1][3]. - The restructuring was intended to enhance Huada Jiutian's capabilities in the electronic design automation (EDA) industry, following its change of control to China Electronics Corporation in December 2024 [1][4]. - The termination of the restructuring also halted Chip and Semiconductor's plans for an independent IPO, which had been initiated in February 2025 [4][5]. Group 2: Financial Performance - In 2024, Huada Jiutian reported revenue of 1.22 billion yuan, a year-on-year increase of 20.98%, but its net profit fell by 45.46% to 109 million yuan [2][8]. - The company's R&D expenses reached 868 million yuan, accounting for 71.02% of its revenue, reflecting a 26.77% increase from the previous year [2][8]. - In the first quarter of 2025, Huada Jiutian achieved revenue of 234 million yuan, a 9.77% increase, while its net profit was 9.71 million yuan, showing a 26.72% year-on-year growth [8]. Group 3: Market Impact - Following the announcement of the restructuring termination, Huada Jiutian's stock price dropped by 5.27% to 108.64 yuan per share, resulting in a market value loss of 3.28 billion yuan [1][6]. - The company's international revenue decreased by 13.32% in 2024, amounting to 57.74 million yuan, which constituted 4.72% of its total revenue [8].

Core Viewpoint - The Chinese pharmaceutical industry is experiencing positive changes driven by policy optimization and innovation, with a focus on internationalization and high-quality development [2][3]. Group 1: Industry Development - China's pharmaceutical industry has become a global leader in the production of active pharmaceutical ingredients (APIs) and small to medium-sized medical devices, playing an increasingly important role in the global pharmaceutical landscape [1][2]. - The industry is transitioning from exporting intermediates and APIs to a comprehensive export of innovative products, marking a significant shift in the internationalization of Chinese pharmaceuticals [2][3]. Group 2: Policy and Regulatory Environment - Recent reforms in drug and medical device regulation have enhanced the safety and effectiveness of products while stimulating innovation within the industry [4][5]. - The acceleration of drug review and approval processes, along with China's membership in the International Council for Harmonisation (ICH), has created a "fast track" for innovative drugs to enter international markets [2][3]. Group 3: Market Strategies and Internationalization - Companies are encouraged to adopt differentiated and refined market entry strategies by analyzing regional market characteristics, disease profiles, payment capabilities, and competitive landscapes [3][4]. - Successful case studies highlight the importance of collaboration, local production, and building partnerships to penetrate target markets effectively [5]. Group 4: Challenges and Future Directions - Despite the progress, the industry faces various internal and external challenges that require modernization of the regulatory system and governance capabilities to ensure high-quality development [3][5]. - The industry must maintain confidence and focus on enhancing innovation capabilities and quality control to navigate complex international environments and competition [5].

【环球时报报道 记者 杨沙沙】编者的话：据美国《华尔街日报》等外媒报道，中国生物科技正迎 来"DeepSeek时刻"。今年以来，中国创新药企巨额"出海"BD（Business Development，商务拓展）交易 频现，其中沈阳三生制药5月宣布向辉瑞授予公司自主研发的突破性PD-1/VEGF双特异性抗体SSGJ-707 在全球（不包括中国内地）的开发、生产、商业化权利，其12.5亿美元首付款创下最高纪录。以前，中 国药企被认为"内卷"严重且缺乏创新性，但从去年年底至今，中国创新药企业出海BD形成了一个高 潮。从引进海外知识产权，到现在反向输出，中国创新药企引起全世界关注。中国从何时开始在制药领 域发力？目前处于哪个梯队？未来中国药企还有哪些增长点？ " 有点像国产手机或是电动汽车 " 《华尔街日报》援引生物医药行业研究机构DealForma的数据说，2020年中国在5000万美元以上的医药 交易中占比不足5%，而到2024年这一比例已上升至近30%。 "这个比例非常可观。"位于硅谷的全球医药创新资本（H7 BioCapital）创始人及首席执行官李梦遥告诉 记者，包括信达、百济神州等中国药企，在海外布局成绩 ...

深入基层调研是我们党推动工作的一种重要方法。习近平总书记强调："要坚持党的群众路线，从群众 中来、到群众中去，深入基层调查研究"。中央八项规定第一项便是改进调查研究，明确要求"到基层调 研要深入了解真实情况"。深入基层调研，关键要"沉到底"，来到一线，抵达民心，夯实根基。 有些党员干部下基层调研并没有一沉到底，而是下到了"夹心层"。看起来到了基层，实质上应付敷衍， 成为一种"作秀"：个别领导干部以工作繁忙、时间紧张为由，下基层只是下到下级部门，看看资料、查 查表格、翻翻台账；到了相对偏远的地方，也是浮于表面，在座谈会等场合听个大概。有的人到基层， 往往是坐在车里"察"民情，隔着车窗"看"基层，会议室里"电话问情况、微信要数据"，宾馆里面听汇 报，做了"井中的葫芦"，看似深到了下面，实则还浮在水面上。"下夹层"不仅不能解决基层的问题，而 且损害党的形象、损害干群关系，让惠民政策在"最后一公里"淤塞，使解决群众急难愁盼成为"纸上承 诺"，最终侵蚀基层治理的根基。 "夹心层"和真正的基层，还隔着好多层，不穿透"夹心层"，很难揪出真问题。"夹心层"里"热热闹闹"， 见到的是笑脸、听到的是好话、看到的是成果；真正的基层 ...

合上这本书，《他们仨》中三位科学家的人生经历在眼前一一闪现，我深为感动，科学家精神竟能在儿 童文学的世界里以如此鲜活的姿态得以描述、展现和传承。在科研之余，我也积极投身于科普工作，常 感慨于孩子们的奇思妙想，他们有那么饱满的热情、那么新奇的想象、那么热切的渴望。我坚信，热爱 和好奇是开启世界奥秘最重要的钥匙。希望孩子们在阅读本书的过程中，真切地感受到科学家的精神力 量，领会到科学的真谛，在心中埋下科学的种子。未来的某一天，这颗种子定会生根发芽，成长壮大。 作为一名植物分类学家，我有时会被问到植物分类学研究有什么用。在我看来，答案不言自明：每一个 植物物种都是地球故事的讲述者，而分类学家就是那个忠实的记录者。 多年来，我在山川湖泽间穿梭，探寻植物的奥秘。当我翻开这本《他们仨》，看到故事里的菌物学家 （"外公"）痴迷于菌物研究、四方奔走的一生，仿佛又回到了那些充满挑战与惊喜的野外科考岁月，不 由感慨万千。野外科考时，我们常戏称自己是"野人"，我们也常怀"野心"，希望探尽物种的奥秘。这本 《他们仨》就将我们的这点痴心和执念，以及这种为穷究科学奥秘忘我钻研的劲头展现给读者。 科学研究的道路漫长而崎岖，充满了无数的艰辛 ...

智通财经7月11日电，丹麦哥本哈根大学与英国剑桥大学领导的研究团队，从欧亚大陆214种已知人类病 原体中成功提取出古代DNA，绘制出跨越数千年的人类传染病图谱，完成了迄今为止关于传染病历史 的最大规模研究，为人与动物互动如何深刻改变人类健康格局提供了重要新见解。这项成果发表在9日 的《自然》杂志上，不仅揭示了人类与病原体之间漫长的博弈历史，也为未来公共卫生策略和疫苗设计 提供了重要参考依据。 新研究绘制数千年人类传染病图谱 ...

以官员：伊朗部分浓缩铀在美以空袭中幸存 金十数据7月11日讯，据纽约时报报道，一位以色列高级官员透露，以色列评估认为伊朗地下储存的部 分接近武器级浓缩铀在上月美以联合空袭中得以保存，这些核材料可能仍可供伊朗核工程师使用。该匿 名官员表示，以色列早在去年底就发现伊朗秘密加速核武研发的迹象，并据此开始筹备军事行动。报道 称，以色列空军击毙黎巴嫩真主党领袖哈桑·纳斯鲁拉后不久，以情报机构便侦测到伊朗的核武活动。 这一发现促使以色列总理内塔尼亚胡着手制定"独立行动"方案。值得关注的是，在6月中旬以色列袭击 伊朗及特朗普决定加入行动期间，美国情报官员曾表示未发现伊朗武器化浓缩铀的证据。 ...

Group 1 - The 10th "Maker China" Shandong Province SME Innovation and Entrepreneurship Competition was launched in Jinan, focusing on the integration of technological and industrial innovation, and the development goals of specialized and innovative SMEs [1] - The competition aims to enhance the internal driving force for development, gain advantages, and build a new highland for innovation and entrepreneurship in Shandong [1] - Since its inception in 2016, the competition has witnessed over 7,000 quality projects and nurtured more than 500 leading enterprises, facilitating over 6 billion RMB in financing for SMEs [1] Group 2 - The competition is divided into two categories: enterprise and entrepreneurship, with three stages: preliminary, semi-final, and final, leading to awards and recommendations for the national finals [3] - Shandong Province has over 30,000 innovative SMEs and 18,000 specialized and innovative SMEs, with 23 national-level characteristic industrial clusters, ranking first in the country [3] Group 3 - Companies like Shandong Tiangong Geotechnical Engineering Equipment Co., Ltd. and Weifang Xingtai Microelectronics Materials Co., Ltd. emphasize the importance of innovation and customer feedback in product development [2] - The latter company has established the only key laboratory for photoresist in Shandong and has broken through Japanese patent barriers with 12 invention patents [2] - Shandong Xinhui Microelectronics Technology Co., Ltd. focuses on deep communication with customers to guide product development based on actual usage feedback [2]